Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes
作者： Adriano Salaroli , Giuseppina Loglisci , Alessandra Serrao , Giuliana Alimena , Massimo Breccia
DOI: 10.1007/S00277-012-1493-3
关键词:
摘要:
springer.com
core.ac.uk
sci-hub.se 参考文章(11)
Jacfranz Guiteau, Michael Fanucchi, Andrew Folpe, Charles A. Staley, David A. Kooby, Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. American Surgeon. ,vol. 72, pp. 1225- 1230 ,(2006) , 10.1177/000313480607201216
N. M. Agostino, V. M. Chinchilli, A. M. Koszyk-Szewczyk, R. Gingrich, J. M. Sivik, J. J. Drabick, Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. Journal of Clinical Oncology. ,vol. 28, pp. 4623- 4623 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.4623
Dariush Mokhtari, Nils Welsh, Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes Clinical Science. ,vol. 118, pp. 241- 247 ,(2010) , 10.1042/CS20090348
Robert Hägerkvist, Stellan Sandler, Dariush Mokhtari, Nils Welsh, Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. The FASEB Journal. ,vol. 21, pp. 618- 628 ,(2007) , 10.1096/FJ.06-6910COM
Stephen Fitter, Kate Vandyke, Christopher G. Schultz, Deborah White, Timothy P. Hughes, Andrew C. W. Zannettino, Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients? The Journal of Clinical Endocrinology and Metabolism. ,vol. 95, pp. 3763- 3767 ,(2010) , 10.1210/JC.2010-0086
David Dingli, Robert Wolf, Adrian Vella, Imatinib and type 2 diabetes. Endocrine Practice. ,vol. 13, pp. 126- 130 ,(2007) , 10.4158/EP.13.2.126
C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier, G. Bollag, S. Zhu, A. Weiss, J. A. Bluestone, Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 18895- 18900 ,(2008) , 10.1073/PNAS.0810246105
Massimo Breccia, Giuliana Alimena, The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leukemia Research. ,vol. 33, pp. 871- 875 ,(2009) , 10.1016/J.LEUKRES.2009.01.040
Paul Hamberg, Floris A. de Jong, Joke G. Boonstra, Jaap van Doorn, Jaap Verweij, Stefan Sleijfer, Non–Islet-Cell Tumor Induced Hypoglycemia in Patients With Advanced Gastrointestinal Stromal Tumor Possibly Worsened By Imatinib Journal of Clinical Oncology. ,vol. 24, ,(2006) , 10.1200/JCO.2006.06.5318
Nicole M Agostino, Vernon M Chinchilli, Christopher J Lynch, Anita Koszyk-Szewczyk, Rebecca Gingrich, Jeffrey Sivik, Joseph J Drabick, Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice Journal of Oncology Pharmacy Practice. ,vol. 17, pp. 197- 202 ,(2011) , 10.1177/1078155210378913